Pharmacology and legal status of cannabidiol.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic synthesis.
PubMed 32959794 · doi:10.4415/ANN_20_03_06
What was done
This review examined the pharmacology of cannabidiol (CBD) and the legal and regulatory frameworks governing the marketing of CBD-containing foods, cosmetics, and pharmaceuticals.
What was found
The abstract reports no quantitative experimental data or statistical findings. It notes that CBD lacks psychotropic properties, mitigates tetrahydrocannabinol (THC)-induced psychotomimetic effects, received US FDA approval in 2018 as Epidiolex® for pediatric Lennox-Gastaut and Dravet syndromes, and currently faces a lack of international regulatory harmonization across consumer and medicinal markets.
Why it matters
It contextualizes the rapid commercial expansion of CBD products against the fragmented international regulatory landscape and established medical indications.
Limits
The abstract describes a non-systematic narrative review with no defined search protocol, quality assessment, or primary data. No empirical measurements or counts of reviewed studies are reported.
Cited by
- supports Cannabidiol (CBD) has received regulatory approval for the treatment of pediatric epilepsy syndromes, specifically Lennox-Gastaut syndrome and Dravet syndrome.